FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Ophthalmol / Determining MMP-2 and MMP-9 reductive activities of bovine a...
Veterinary ophthalmology2021; 24(3); 279-287; doi: 10.1111/vop.12888

Determining MMP-2 and MMP-9 reductive activities of bovine and equine amniotic membranes homogenates using fluorescence resonance energy transfer.

Abstract: Matrix metalloproteinases (MMPs)-2 and -9 are present in corneal ulcers, and an imbalance between MMPs and tissue inhibitors of metalloproteinases (TIMPs) leads to further corneal degradation. Amniotic membrane homogenate (AMH) has proteolytic properties beneficial for corneal healing, but it is unknown whether AMH possesses TIMPs or effectively inhibits MMP-2 and MMP-9 activity. Objective: To determine if bovine and equine AMH reduce in vitro MMP-2 and MMP-9 activities associated with the presence of TIMPs. Methods: Undiluted and diluted twofold series (0-fold to 16-fold dilutions) of equine amniotic membrane homogenates (EAMH, n = 8) and bovine amniotic membrane homogenates (BAMH, n = 8) were subjected to fluorescence resonance energy transfer, and the fluorescence emitted was recorded over time. Average fluorescence was calculated versus recombinant concentration. Enzyme-linked immunosorbent assays for TIMPs 1-4 were applied to quantify TIMPs in the samples. Results: AMH from both species were able to inhibit MMP-2 and MMP-9 activities in vitro, and the inhibition efficacy decreased gradually with dilution. BAMH was significantly more effective than EAMH at inhibiting MMP-2 and MMP-9 in vitro. TIMPs -2 and -3 were present in EAMH and BAMH. TIMP-1 was detected only in BAMH, and TIMP-4 was not detected in any samples. Conclusions: Both EAMH and BAMH directly inhibited MMP-2 and MMP-9 in vitro without dilution, and BAMH showed better inhibition of MMP-2 and MMP-9 before and after dilution compared to EAMH.
© 2021 American College of Veterinary Ophthalmologists.
Get Full Text
Publication Date: 2021-04-09 PubMed ID: 33834598DOI: 10.1111/vop.12888Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates whether amniotic membrane homogenates from bovines and equines can reduce the activity of harmful enzymes associated with corneal ulcers. The research confirmed that these animal-derived substances can indeed inhibit these enzymes, with bovine-derived substances proving more effective, suggesting potential therapeutic applications.

Understanding the Research Context

  • The research deals specifically with enzymes called matrix metalloproteinases (MMPs)-2 and -9, which are associated with the development of corneal ulcers. These enzymes contribute to the breakdown of corneal tissue, worsening the condition.
  • Another factor in this disease process is an imbalance between these MMPs and what are known as tissue inhibitors of metalloproteinases (TIMPs). When the amount of TIMPs is insufficient, the MMPs go unchecked, further accelerating tissue breakdown.
  • The researchers aimed to investigate whether amniotic membrane homogenates (AMHs) from bovine and equine sources can act as TIMPs to inhibit the activity of MMP-2 and MMP-9. The theory is based on the known proteolytic properties of AMH that favor corneal healing.

Methodology Followed in the Research

  • The researchers extracted amniotic membrane homogenates (AMH) from both bovines (BAMH) and equines (EAMH).
  • They used a fluorescence resonance energy transfer (FRET) approach to assess the inhibition of MMP-2 and MMP-9 activities by AMH. The fluorescence emitted during this transfer was recorded over time, and its average value calculated against recombinant concentration.
  • The presence and quantity of TIMPs in these samples were also verified using enzyme-linked immunosorbent assays (ELISAs) for TIMPs 1-4.

Key Findings of the Study

  • Dragonfly
  • It was observed that AMH from both species effectively inhibited MMP-2 and MMP-9 activities in vitro. However, the results showed the effectiveness of this inhibition gradually decreased with dilution.
  • When compared, BAMH was found to be significantly more effective than EAMH at inhibiting MMP-2 and MMP-9.
  • In terms of TIMP content, both AMHs contained TIMP-2 and TIMP-3. TIMP-1 was only present in BAMH, while TIMP-5 could not be detected in any of the samples.

Conclusions Drawn from the Research

  • Bovine and equine AMH could inhibit the activities of MMP-2 and MMP-9 directly and without dilution. This implies that AMH use could potentially provide a therapeutic strategy for corneal ulcers.
  • Between the two, BAMH proved to be more efficient at inhibiting MMP-2 and MMP-9, both undiluted and after successive dilutions. This suggests that BAMH might be the more viable option for therapeutic use in this context.

Cite This Article

APA
Capistrano da Silva E, Gibson DJ, Jeong S, Zimmerman KL, Smith-Fleming KM, Martins BDC. (2021). Determining MMP-2 and MMP-9 reductive activities of bovine and equine amniotic membranes homogenates using fluorescence resonance energy transfer. Vet Ophthalmol, 24(3), 279-287. https://doi.org/10.1111/vop.12888

Publication

Veterinary ophthalmology
ISSN: 1463-5224
NlmUniqueID: 100887377
Country: England
Language: English
Volume: 24
Issue: 3
Pages: 279-287

Researcher Affiliations

Capistrano da Silva, Erotides
  • Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA.
Gibson, Daniel J
  • Department of Obstetrics and Gynecology, College of Medicine, University of Florida, Gainesville, FL, USA.
Jeong, Sunyoung
  • Department of Obstetrics and Gynecology, College of Medicine, University of Florida, Gainesville, FL, USA.
Zimmerman, Kelli L
  • Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA.
Smith-Fleming, Kathryn M
  • Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA.
Martins, Bianca da C
  • Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA.
  • Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, IL, USA.

MeSH Terms

  • Amnion / metabolism
  • Animals
  • Cattle
  • Female
  • Fluorescence Resonance Energy Transfer / veterinary
  • Horses
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • Pregnancy

Grant Funding

  • 0000 / University of Illinois at Urbana-Champaign

References

This article includes 54 references
  1. Ollivier FJ, Gilger BC, Barrie KP. Proteinases of the cornea and preocular tear film.. Vet Ophthalmol 2007;10(4):199-206.
  2. Nishida T. Part I - Basic Science: Cornea, Sclera, Ocular Adnexa Anatomy, Physiology and Pathophysiologic Responses. In: Krachmer JH, Mannis MHM, eds. Cornea - Fundamentals, diagnosis and managements. Vol. 1. 1st ed. St. Louis, MO: Mosby; 1997.
  3. Twining SS, Fukuchi T, Yue BYJT, Wilson PM, Boskovic G. Corneal synthesis of α1-proteinase inhibitor (α1-antitrypsin).. Investig Ophthalmol Vis Sci 1994;35(2):458-462.
  4. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs.. Cardiovasc Res 2006;69(3):562-573.
    doi: 10.1016/j.cardiores.2005.12.002google scholar: lookup
  5. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.. Prostate Cancer Prostatic Dis 2003;6(3):217-222.
    doi: 10.1038/sj.pcan.4500657google scholar: lookup
  6. Kenney MC, Chwa M, Alba A, Saghizadeh M, Huang Z, Brown DJ. Localization of TIMP-1, TIMP-2, TIMP-3, gelatinase A and gelatinase B in pathological human corneas M.. Curr Eye Res 1998;17:238-246.
  7. Zeng Y, Rosborough RC, Li Y, Gupta AR, Bennett J. Temporal and spatial regulation of gene expression mediated by the promoter for the human tissue inhibitor of metalloproteinases-3 (TIMP-3)- encoding gene.. Dev Dyn 1998;211(3):228-237.
    doi: 10.1002/(sici)1097-0177(199803)211:3<228:aid-aja4>3.0.co;2-jgoogle scholar: lookup
  8. Ma DHK, Zhang F, Shi W. Expression of tissue inhibitor of metalloproteinase-4 in normal human corneal cells and experimental corneal neovascularization.. Ophthalmic Res 2003;35(4):199-207.
    doi: 10.1159/000071171google scholar: lookup
  9. Ledbetter EC, Gilger CG. Disease and surgery of the canine cornea and sclera. In: Gelatt KN, Gilger BC, Kern TJ, eds. Veterinary Ophthalmology, 5th edn. Ames, IA: Wiley-Blackwell; 2013:978-993.
  10. Lassaline ME, Brooks DE, Ollivier FJ, Komaromy AM, Kallberg ME, Gelatt KN. Equine amniotic membrane transplantation for corneal ulceration and keratomalacia in three horses.. Vet Ophthalmol 2005;8(5):311-317.
    doi: 10.1111/j.1463-5224.2005.00405.xgoogle scholar: lookup
  11. Kim JS, Kim JC, Na BK, Jeong JM, Song CY. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn.. Exp Eye Res 2000;70(3):329-337.
    doi: 10.1006/exer.1999.0794google scholar: lookup
  12. Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes.. Ocul Surf 2004;2(3):201-211.
    doi: 10.1016/s1542-0124(12)70062-9google scholar: lookup
  13. Talmi YP, Sigler L, Inge E, Finkelstein Y, Zohar Y. Antibacterial properties of human amniotic membranes.. Placenta 1991;12(3):285-288.
    doi: 10.1016/0143-4004(91)90010-dgoogle scholar: lookup
  14. Choi JA, Jin HJ, Jung S. Effects of amniotic membrane suspension in human corneal wound healing in vitro.. Mol Vis 2009;15:2230-2238.
  15. Kamiya K, Wang M, Uchida S. Topical application of culture supernatant from human amniotic epithelial cells suppresses inflammatory reactions in cornea.. Exp Eye Res 2005;80(5):671-679.
    doi: 10.1016/j.exer.2004.11.018google scholar: lookup
  16. Wichayacoop T, Briksawan P, Tuntivanich P, Yibchok-Anun S. Anti-inflammatory effects of topical supernatant from human amniotic membrane cell culture on canine deep corneal ulcer after human amniotic membrane transplantation.. Vet Ophthalmol 2009;12(1):28-35.
    doi: 10.1111/j.1463-5224.2009.00670.xgoogle scholar: lookup
  17. Guo Q, Hao J, Yang Q, Guan L, Ouyang S, Wang J. A comparison of the effectiveness between amniotic membrane homogenate and transplanted amniotic membrane in healing corneal damage in a rabbit model.. Acta Ophthalmol 2011;89(4):315-319.
    doi: 10.1111/j.1755-3768.2010.02097.xgoogle scholar: lookup
  18. Murri MS, Moshirfar M, Birdsong OC, Ronquillo YC, Ding Y, Hoopes PC. Amniotic membrane extract and eye drops: a review of literature and clinical application.. Clin Ophthalmol 2018;12:1105-1112.
    doi: 10.2147/opth.s165553google scholar: lookup
  19. Baradaran-Rafii A, Asl NS, Ebrahimi M. The role of amniotic membrane extract eye drop (AMEED) in in vivo cultivation of limbal stem cells.. Ocul Surf 2018;16(1):146-153.
    doi: 10.1016/j.jtos.2017.11.001google scholar: lookup
  20. Liang L, Li W, Ling S. Amniotic membrane extraction solution for ocular chemical burns.. Clin Exp Ophthalmol 2009;37(9):855-863.
    doi: 10.1111/j.1442-9071.2009.02159.xgoogle scholar: lookup
  21. Kordic R, Popovic Suic S, Jandrokovic S. Application of the amniotic membrane extract (AMX) for the persistent epithelial defect (PED) of the cornea.. Coll Antropol 2013;37(1):161-164.
  22. Barros PSM, Garcia JA, Laus JL, Ferreira AL, Salles Gomes TL. The use of xenologous amniotic membrane to repair canine corneal perforation created by penetrating keratectomy.. Vet Ophthalmol 1998;1(2-3):119-123.
    doi: 10.1046/j.1463-5224.1998.00026.xgoogle scholar: lookup
  23. Goodrich LR, Moll HD, Crisman MV, Lessard P, Bigbie RB. Comparison of equine amnion and a nonadherent wound dressing material for bandaging pinch-grafted wounds in ponies.. Am J Vet Res 2000;61(3):326-329.
    doi: 10.2460/ajvr.2000.61.326google scholar: lookup
  24. Perepelkin NMJ, Hayward K, Mokoena T. Cryopreserved amniotic membrane as transplant allograft: viability and post-transplant outcome.. Cell Tissue Bank 2016;17(1):39-50.
    doi: 10.1007/s10561-015-9530-9google scholar: lookup
  25. McCoy AM, Arrington J, Yau PM. Effect of preparation method on the protein profile of equine amnion dressings.. J Proteome Res 2019;18:2676-2685.
  26. Kruse FE, Joussen AM, Rohrschneider K. Cryopreserved human amniotic membrane for ocular surface reconstruction.. Graefe’s Arch Clin Exp Ophthalmol 2000;238(1):68-75.
    doi: 10.1007/s004170050012google scholar: lookup
  27. Bomfim Pereira MG, Pereira Gomes JA, Rizzo LV, Cristovam PC, Silveira LC. Cytokine dosage in fresh and preserved human amniotic membrane.. Cornea 2016;35(1):89-94.
  28. Rodella A, Pozzobon M, Rigon M. Topical application of lyophilized and powdered human amniotic membrane promotes diabetic ulcer healing.. Wound Med 2019;27(1):100171.
    doi: 10.1016/j.wndm.2019.100171google scholar: lookup
  29. Lyons VN, Townsend WM, Moore GE, Liang S. Commercial amniotic membrane extract for treatment of corneal ulcers in adult horses.. Equine Vet J 2020:00:1-9.
    doi: 10.1111/evj.13399google scholar: lookup
  30. Plummer CE. The use of amniotic membrane transplantation for ocular surface reconstruction: a review and series of 58 equine clinical cases (2002-2008).. Vet Ophthalmol 2009;12(Suppl. 1):17-24.
    doi: 10.1111/j.1463-5224.2009.00741.xgoogle scholar: lookup
  31. Ollivier FJ, Brooks DE, Kallberg ME. Evaluation of various compounds to inhibit activity of matrix metalloproteinases in the tear film of horses with ulcerative keratitis.. Am J Vet Res 2003;64(9):1081-1087.
    doi: 10.2460/ajvr.2003.64.1081google scholar: lookup
  32. Peter AT, Amin Beg M, Ahmad E, Bergfelt DR. Trophoblast of domestic and companion animals: basic and applied clinical perspectives.. Anim Reprod 2017;14:1209-1224.
    doi: 10.21451/1984-3143-ar973google scholar: lookup
  33. Fortunato SJ, Ramkumar Menon SJL. Presence of four tissue inhibitors of matrix human fetal membranes.. Am J Reprod Immunol 1998;40:395-400.
  34. Niu R, Okamoto T, Iwase K, Nomuta SMS. Quantitative analysis of matrix metaloproteinases-2 and -9, and their tissue inhibitors-1 and -2 in human placenta throughout gestation.. Life Sci 2000;66(12):1127-1137.
  35. Streyl D, Kenngott R, Herbach N. Gene expression profiling of bovine peripartal placentomes: detection of molecular pathways potentially involved in the release of foetal membranes.. Reproduction 2012;143(1):85-105.
    doi: 10.1530/rep-11-0204google scholar: lookup
  36. Walter I, Boos A. Matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitor-2 of matrix metalloproteinases (TIMP-2) in the placenta and interplacental uterine wall in normal cows and in cattle with retention of fetal membranes.. Placenta 2001;22(5):473-483.
    doi: 10.1053/plac.2001.0633google scholar: lookup
  37. Rapacz-Leonard A, Kankofer M, Leonard M. Differences in extracellular matrix remodeling in the placenta of mares that retain fetal membranes and mares that deliver fetal membranes physiologically.. Placenta 2015;36(10):1167-1177.
    doi: 10.1016/j.placenta.2015.07.126google scholar: lookup
  38. Enders AC, Carter AM. What can comparative studies of placental structure tell us?-A review.. Placenta 2004;25:S3-S9.
    doi: 10.1016/j.placenta.2004.01.011google scholar: lookup
  39. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4.. J Biol Chem 1996;271(48):30375-30380.
    doi: 10.1074/jbc.271.48.30375google scholar: lookup
  40. Sapsford KE, Berti L, Medintz IJ. Fluorescence resonance energy transfer.. Minerva Biotechnol 2004;253-279.
  41. Ogawa M, Kosaka N, Longmire M, Urano Y. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases Mikako.. Mol Pharm 2009;6(2):386-395.
    doi: 10.1038/jid.2014.371google scholar: lookup
  42. Keith Brew HN. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity Keith.. Biochim Biophys Acta 2010;1803(1):55-71.
    doi: 10.1038/jid.2014.371google scholar: lookup
  43. Ries C. Cytokine functions of TIMP-1.. Cell Mol Life Sci 2014;71(4):659-672.
    doi: 10.1007/s00018-013-1457-3google scholar: lookup
  44. Vandooren J, Knoops S, Buzzo JLA. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: a comparative study.. PLoS One 2017;12(4):1-19.
    doi: 10.1371/journal.pone.0174853google scholar: lookup
  45. Galera PD, Ribeiro CR, Sapp HL, Coleman J, Fontes W, Brooks DE. Proteomic analysis of equine amniotic membrane: characterization of proteins.. Vet Ophthalmol 2015;18(3):198-209.
    doi: 10.1111/vop.12190google scholar: lookup
  46. Bertolini M, Wallace CR, Anderson GB. Expression profile and protein levels of placental products as indirect measures of placental function in in vitro-derived bovine pregnancies.. Reproduction 2006;131(1):163-173.
    doi: 10.1530/rep.1.00739google scholar: lookup
  47. Emmert-Buck MR, Emonard HP, Corcoran ML, Krutzsch HC, Foidart JM, Stetler-Stevenson WG. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex.. FEBS Lett 1995;364(1):28-32.
    doi: 10.1016/0014-5793(95)00345-agoogle scholar: lookup
  48. Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.. Biochem J 2003;374(3):739-745.
    doi: 10.1042/bj20030557google scholar: lookup
  49. Mocchegiani E, Giacconi R, Muti E, Muzzioli M, Cipriano C. Zinc-binding proteins (metallothionein and α-2 macroglobulin) as potential biological markers of immunosenescence.. NeuroImmune Biol 2004;4:23-40.
    doi: 10.1016/s1567-7443(04)80004-8google scholar: lookup
  50. Frochaux V, Hildebrand D, Talke A, Linscheid MW, Schlüter H. Alpha-1-antitrypsin: a novel human high temperature requirement protease A1 (HTRA1) substrate in human placental tissue.. PLoS One 2014;9(10):1-12.
    doi: 10.1371/journal.pone.0109483google scholar: lookup
  51. Tayade C, Esadeg S, Fang Y, Croy BA. Functions of alpha 2 macroglobulins in pregnancy.. Mol Cell Endocrinol 2005;245(1-2):60-66.
    doi: 10.1016/j.mce.2005.10.004google scholar: lookup
  52. Singh A, Maurya OPS, Jagannadhan MV, Patel A. Matrix metalloproteinases (MMP-2 and MMP-9) activity in corneal ulcer and ocular surface disorders determined by gelatin zymography.. J Ocul Biol Dis Infor 2012;5(2):31-35.
    doi: 10.1007/s12177-012-9096-8google scholar: lookup
  53. Brooks DE, Ollivier FJ. Matrix metalloproteinase inhibition in corneal ulceration.. Vet Clin North Am Small Anim Pract 2004;34(3):611-622.
    doi: 10.1016/j.cvsm.2003.12.005google scholar: lookup
  54. Capistrano da Silva E, Arrington J, Yau PM, Smith-Fleming KM, Canisso IF, Martins BC. Proteome composition of bovine amniotic membrane and its potential role in corneal healing.. Investig Opthalmol Vis Sci 2021;62(2):11.

Citations

This article has been cited 1 times.
  1. Permkam C, Suriyaphol G, Sirisawadi S, Tuntivanich N. Biological Compositions of Canine Amniotic Membrane and Its Extracts and the Investigation of Corneal Wound Healing Efficacy In Vitro. Vet Sci 2022 May 9;9(5).
    doi: 10.3390/vetsci9050227pubmed: 35622755google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.